Exploring Ketamine Analgosedation Use and Its Effect on Incident Delirium in Critically Ill Adults by Wu, T.T. et al.






The following full text is a publisher's version.
 
 












































Critical Care Explorations www.ccejournal.org     1
DOI: 10.1097/CCE.0000000000000544
Copyright © 2021 The Authors. 
Published by Wolters Kluwer Health, 
Inc. on behalf of the Society of Critical 
Care Medicine. This is an open-access 
article distributed under the terms of 
the Creative Commons Attribution-
Non Commercial-No Derivatives 
License 4.0 (CCBY-NC-ND), where it 
is permissible to download and share 
the work provided it is properly cited. 
The work cannot be changed in any 
way or used commercially without 
permission from the journal.
OBJECTIVES: Ketamine is increasingly being used for analgosedation, but its 
effect on delirium remains unclear. We compared delirium risk variables and ke-
tamine analgosedation use between adults who developed incident delirium and 
those who did not, evaluated whether ketamine analgosedation increases delirium 
risk, and compared ICU delirium characteristics, treatments, and outcomes be-
tween ketamine and nonketamine patients with delirium.
DESIGN: Secondary, subgroup analysis of a cohort study.
SETTING: Single, 36-bed mixed medical-surgical ICU in the Netherlands from 
July 2016 to February 2020.
PATIENTS: Consecutive adults were included. Patients admitted after elective 
surgery, not expected to survive greater than or equal to 48 hours, admitted with 
delirium, or where delirium occurred prior to ketamine use were excluded.
INTERVENTION: None.
MEASUREMENTS AND MAIN RESULTS: Trained ICU nurses evaluated 
patients without coma (Richmond Agitation Sedation Scale. –4/–5) every 
8 hours with the Confusion Assessment Method ICU; a delirium day was 
defined by greater than or equal to1 + Confusion Assessment Method ICU 
and/or scheduled antipsychotic use. Among 11 variables compared between 
the delirium and nondelirium groups (Baseline: age, Charlson Comorbidity 
score, cognitive impairment, admission type, and Acute Physiology and Chronic 
Health Evaluation-IV score, daily ICU [until delirium occurrence or discharge]: 
Sequential Organ Failure Assessment score, coma, benzodiazepine, opioid, and 
ketamine use) and total ICU days, 7 (age, Charlson score, Sequential Organ 
Failure Assessment score, coma, benzodiazepine, opioid, and ketamine use) 
were significantly different and were entered, along with delirium occurrence, 
in a logistic regression model. A total of 332 of 925 of patients (36%) devel-
oped delirium. Ketamine use was greater in patients with delirium (54 [16%] vs 
4 [0.7%]; p < 0.01). Ketamine use (adjusted odds ratio, 5.60; 95% CI, 1.09–
29.15), age (adjusted odds ratio, 1.03; 95% CI, 1.01–1.06), coma (adjusted 
odds ratio, 2.10; 95% CI, 1.15–3.78), opioid use (adjusted odds ratio, 171.17; 
95% CI, 66.45–553.68), and benzodiazepine use (adjusted odds ratio, 34.07; 
95% CI, 8.12–235.34) were each independently and significantly associated 
with increased delirium. Delirium duration, motoric subtype, delirium treatments, 
and outcomes were not different between the ketamine and nonketamine 
groups.
CONCLUSIONS: Ketamine analgosedation may contribute to increased ICU 
delirium. The characteristics of ketamine and nonketamine delirium are similar. 
Further prospective research is required to evaluate the magnitude of risk for de-
lirium with ketamine use.
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Ketamine, an anesthetic with both analgesic and sedative properties, is increasingly being used in both surgical and medical critically ill adults 
for analgosedation (1–3). Delirium, a common sequela 
of critical illness, is associated with poor outcomes (4). 
Medications, including benzodiazepines (5) and opi-
oids (6), are well-established risk factors for delirium in 
the ICU. Ketamine, an N-methyl-d-aspartate receptor 
antagonist, results in a dissociative state clinically man-
ifesting as catatonia and amnesia, and is associated in 
a dose-dependent fashion with hallucinations and psy-
chosis (7). Similarities exist between the clinical effects 
of ketamine and the symptoms of delirium (4).
One randomized trial (8) and four cohort studies 
(9–12) have evaluated delirium in critically ill adults 
managed with ketamine analogosedation. In the ran-
domized trial (8), the ketamine dose administered was 
low and fixed, and compared with the placebo group, 
the ketamine group received fewer opioids, an impor-
tant dose-related risk for delirium (6). None of the ICU 
cohort studies reported a difference in delirium with 
ketamine use (9–12). However, none of these studies 
considered the presence of other potential baseline 
and ICU delirium risk factors nor ensured delirium 
occurred after ketamine was started. The risk for ICU 
delirium with ketamine analgosedation and the char-
acteristics and outcomes of delirium that occur after its 
initiation remain poorly characterized. We compared 
variables, including ketamine analgosedation use, be-
tween critically ill adults who developed ICU incident 
delirium and those who did not, evaluated whether 
ketamine analgosedation increases delirium risk, 
and compared delirium characteristics, treatments, 
and outcomes between ketamine and nonketamine 
patients who developed delirium.
MATERIALS AND METHODS
Design, Setting, and Patients
This cohort study is a post hoc, secondary, subgroup 
analysis of the Monitoring cOnsequeNces of InTensive 
care fOR Intensive Care patients (MONITOR-IC) 
study (ClinicalTrials.gov NCT03246334) (13, 14). 
The multicenter, MONITOR-IC cohort study pro-
spectively compared patient self-reported cog-
nitive, psychologic, and physical health statuses 
before and 1 year after ICU admission in 2,345 
critically ill adults in the Netherlands (13, 14). 
The Strengthening the Reporting of Observational 
Studies in Epidemiology guidelines were followed 
throughout the study (15).
Consecutive patients enrolled in the MONITOR-IC 
study between July 2016 and February 2020 who were 
admitted to the 36-bed mixed medical-surgical ICU at 
RadboudUMC, Nijmegen, NL, were included in our 
analysis. Patients admitted after elective surgery or not 
expected by the ICU attending physician to survive 
greater than or equal to 48 hours were excluded. Risk 
factors for delirium are different between elective sur-
gery and critically ill adults admitted to the ICU (16, 17). 
At RadboudUMC, ketamine use after elective surgery 
is usually administered at a low dose as part of mul-
timodal analgesia and is rarely administered at the 
higher doses used for analgosedation (1, 2, 4). Patients 
with delirium at ICU admission, who developed ICU 
delirium prior to or on the same day as ketamine in-
itiation, or who received ketamine for a nonanalgose-
dation indication (e.g., status asthmaticus) were also 
excluded. Although use of the “A” for Assessment, 
Prevention, and Manage pain; “B” for Both Spontaneous 
Awakening Trials and Spontaneous Breathing Trials; 
“C” for Choice of Analgesia and Sedation; “D” for 
Delirium Assess, Prevent, and Manage; “E” for Early 
Mobility and Exercise; and “F” for Family Engagement 
and Empowerment (ABCDEF) bundle is established 
the RadboudUMC ICU (18), sedative choice, in-
cluding the use of ketamine for analgosedation, is not 
protocolized. This study was approved by the ethics 
committee of the RadboudUMC (2016-2724). Each 
participant, or their legal representative, provided 
written informed consent.
Outcomes
Baseline demographic data were obtained from the 
Monitor-IC study database. All remaining patient data 
were extracted from the RadboudUMC Epic (Verona, 
WI) electronic health record by trained research per-
sonnel. Data on daily ICU ketamine use, including 
the average daily infusion dose (mg/kg/hr), were col-
lected. Well-trained ICU nurses evaluated all patients 
without coma (Richmond Agitation Sedation Scale 
[RASS] score, –4/–5) (19) for delirium every 8 hours 
using the Confusion Assessment Method-ICU (CAM-
ICU) (20). When possible, delirium assessments were 
conducted when the patient was maximally awake. 
A day with delirium was defined by greater than or 
equal to 1 positive CAM-ICU assessment or scheduled 
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antipsychotic use (21). This combined delirium defini-
tion is based on the frequent use of haloperidol/que-
tiapine for ICU delirium treatment at RadboudUMC 
and concerns the sensitivity of the CAM-ICU to detect 
delirium by bedside clinicians, even after training, is 
not as high as that seen with research personnel (22).
The duration of ICU stay before incident delirium 
occurrence (or discharge) and data for n = 9 poten-
tial ICU delirium risk factors (Pre-ICU: age, Modified 
Charlson Comorbidity score, presence of cognitive 
impairment [Cognitive Failure Questionnaire Score 
≥ 43]; ICU baseline: admission type [medical or ur-
gent surgery], Acute Physiologic and Chronic Health 
Evaluation [APACHE] IV score; and daily ICU [until 
delirium occurrence or discharge]: average Sequential 
Organ Failure Assessment [SOFA] score, coma days, 
daily ICU benzodiazepine use [≥ 5-mg IV midazolam 
equivalents], and opioid use [≥ 10 IV morphine mil-
ligram equivalents, MME]) were collected. Each of 
these factors is well established in the literature as risk 
factors for delirium in critically ill adults (4–6, 17, 23). 
For patients who developed incident delirium, the mo-
toric subtype was categorized as either hyperactive 
(+CAM-ICU with RASS > 0 or any scheduled anti-
psychotic use), hypoactive (+CAM-ICU with RASS ≤ 
0), or mixed (mix of both hyperactive and hypoactive) 
(23). Data on the daily ICU use of opioids (≥ 10 IV 
MME)/d, scheduled nonopioid analgesics (i.e., aceta-
minophen, pregabalin, and gabapentin), sedatives (i.e., 
benzodiazepines [≥ 5 mg IV midazolam equivalents/d], 
IV clonidine, dexmedetomidine, or propofol), antipsy-
chotics (IV haloperidol and quetiapine), and restraints 
were also collected. Data on ICU days spent with de-
lirium and mechanical ventilation, ICU length of stay, 
and ICU mortality were also collected.
Analysis
Incident ICU delirium was the primary end point 
of our analysis; ketamine use was the independent 
variable and incident delirium the dependent vari-
able. We compared the nine potential delirium risk 
factors, ICU ketamine use, and ICU days (before 
delirium or discharge) between the delirium and no-
delirium groups. With the exception of the baseline 
APACHE-IV score, we included all variables signif-
icantly different between the delirium and no-delir-
ium groups, ketamine use, and delirium occurrence 
in a logistic regression model. With only 58 (6.3%) 
of the study cohort exposed to ketamine and con-
cerns about model overfitting, we eliminated base-
line APACHE-IV score as a model variable because 
daily ICU SOFA score is a more robust estimate of 
severity of illness during the ICU stay. We, there-
fore, included six delirium risk variables in the model 
(i.e., age, modified Charlson Comorbidity Score, and 
ICU SOFA score, coma, and opioid and benzodiazepine 
use prior to delirium occurrence [or ICU discharge]). 
To address our second objective, we compared rele-
vant baseline and ICU variables between ketamine and 
nonketamine patients who developed ICU incident 
delirium. Days of medication (e.g., haloperidol) or 
nonmedication interventions (e.g., restraints) after de-
lirium occurrence were not considered. Dichotomous 
variable data were presented as n (%) and compared 
using the chi-square test. All continuous variable data 
were deemed not to be normally distributed and, 
thus, were presented as a median (interquartile range 
[IQR]) and compared using the Wilcoxon rank-sum 
test. Random data missingness was low (< 5%) for all 
variables. A p value of less than 0.05 was deemed sig-
nificant. All analyses were performed using R Version 
4.0.3 (R Foundation for Statistical Computing, 2020).
RESULTS
As outlined in Figure 1, among 3,160 MONITOR-IC 
trial patients screened for participation in the anal-
ysis, 2,149 were initially excluded. Among the 1,011 
remaining patients, 75 received ketamine and 936 
did not. After excluding patients admitted to the ICU 
with delirium or who developed delirium prior to ke-
tamine use, 925 (58 ketamine and 867 nonketamine) 
patients were included in the final analysis. No patient 
received ketamine for a nonanalgosedation indication. 
Delirium occurred in 332/925 patients (56%) for a me-
dian (IQR) 2 (1–5)days.
Univariate analysis revealed age, Modified Charlson 
Comorbidity score, APACHE-IV score, ketamine use, 
SOFA score, coma, opioid use, and benzodiazepine use 
to be significantly higher/greater in the delirium group 
(Table 1). Baseline cognitive impairment, ICU admis-
sion for urgent surgery (vs a medical condition), and 
days spent in the ICU were not different between de-
lirium and nondelirium groups. The logistic regression 
analysis revealed ketamine use (adjusted odds ratio 
[aOR], 5.56; 95% CI, 1.09–28.65; p = 0.04), coma (aOR, 
2.10; 95% CI, 1.15–3.78), opioid use (aOR, 171.17; 
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95% CI, 66.45–553.68), and benzodiazepine use (aOR, 
34.07; 95% CI, 8.12–235.34) each to be independently 
and significantly associated with greater incident ICU 
delirium (Table 2).
The median (IQR) ketamine dose was more than four 
times higher in the delirium (vs no delirium) group, 
but this difference did not reach statistical significance 
(0.50 mg/kg/hr [0.17–0.83 mg/kg/hr] vs 0.12 mg/kg/hr 
[0.06–0.29 mg/kg/hr]; p = 0.10). Daily ICU delirium 
prevalence for ketamine-exposed patients, as a propor-
tion of patients remaining in the ICU on each day, is 
presented in Figure 2. The results of the comparison 
between the n = 54 ketamine and n = 278 nonket-
amine patients who developed delirium are presented 
in Table  3. The ketamine (vs nonketamine) delirium 
groups were more likely to be admitted to the ICU for/
after urgent surgery and administered an opioid or IV 
clonidine prior to delirium. However, the average daily 
opoid dose (in IV MME) on days of opioid exposure 
prior to delirium occurrence was not different between 
the two groups. No pa-
tient received an antipsy-
chotic prior to delirium 
occurrence. After delirium 
occurrence, use of opioids, 
nonopioid analgesics, seda-
tives, and antipsychotics 
were not different between 
ketamine and nonketamine 
delirium groups. The dura-
tion of ICU delirium and its 
motoric subtypes were sim-
ilar between the two groups. 
Outcomes, including dura-
tion of mechanical ventila-
tion, ICU length of stay, and 
ICU mortality, were also 
not different between the 
two groups.
DISCUSSION
Our results suggest keta-
mine, when administered 
to critically ill surgical and 
medical patients requir-
ing analgosedation, may 
increase the risk for ICU 
incident delirium. Age, 
coma, opioid use, and benzodiazepine use were also 
each independently associated with a greater delirium 
risk. With the exception that patients admitted to the 
ICU for urgent surgery were more likely to develop de-
lirium with ketamine and more ketamine patients with 
delirium received opioid and IV clonidine therapy, 
other delirium risks, motorotic subtypes, treatments, 
and ICU outcomes were similar between the ketamine 
and nonketamine patients who developed delirium.
Ketamine, with its lack of effect on respiratory drive 
and low propensity to cause hypotension or coma, has 
advantages over opioids and propofol in critically ill 
adults requiring analgosedation (1, 2). Ketamine is in-
creasingly being used to optimize ICU patient comfort 
and safety (3) despite the current lack of a large, mul-
ticenter, controlled trial evaluating its analgosedation 
safety and efficacy (3). The pharmacology of ketamine 
is complex, and dose-dependent: analgesic effects usu-
ally predominate at lower doses (0.1–0.4 mg/kg/hr) and 
sedative effects at higher doses (0.4–1.0 mg/kg/hr) (1, 2). 
Figure 1. Study flowchart.
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TABLE 1. 
Comparison of Potential Delirium Risk Factors Between Patients With and Without ICU 
Delirium
Variables
All Patients  
(n = 925)
Incident Delirium Occurrence
Yes (n = 332) No (n = 593) p
Pre-ICU admission variables
 Age, median (IQR) 62 (51–71) 64 (53–72) 60 (49–70) < 0.01
 Modified Charlson Comorbidity Score, median (IQR) 2 (1–4) 3 (2–4) 2 (1–3) 0.03
 Cognitive impairment, n (%) 39 (4.2) 17 (5.1) 22 (3.7) 0.33
ICU baseline variables
 Admission type, n (%)
  Medical 594 (64.2) 208 (62.7) 386 (65.1) 0.50
  Urgent surgery 331 (35.8) 124 (37.3) 207 (34.9) 0.50
 Acute Physiologic and Chronic Health Evaluation IV score,  
  median (IQR)
67 (52–83) 76 (62–95) 61 (47–77) < 0.01
ICU clinical variablesa  
 Ketamine exposure, n (%) 58 (6.3) 54 (16.3) 4 (0.7) < 0.01
 Sequential Organ Failure Assessment score, median (IQR) 6.0 (3.6–8.3) 8.2 (6.0–10.5) 4.7 (2.9–6.8) < 0.01
 Presence of coma, n (%) 346 (37.4) 221 (66.6) 125 (21.1) < 0.01
 Opioid exposure (IV or oral), n (%)b 263 (28.4) 258 (77.7) 5 (0.8) < 0.01
 Benzodiazepine exposure (IV or oral), n (%)c 171 (18.5) 169 (50.9) 2 (0.3) < 0.01
 ICU days, median (IQR) 2.0 (1.0–3.8) 2.8 (0.8–4.8) 2.0 (1.0–3.0) 0.30
IQR = interquartile range.
aPrior to delirium (or ICU discharge).
bAverage IV morphine equivalent dose ≥ 10 mg/d.
cAverage midazolam equivalent dose ≥ 5 mg/d.
TABLE 2. 
Association Between Ketamine Use and Other Variables and ICU Delirium Occurrence
Variables
Delirium Occurrence
Adjusted OR (95% CI) p
Pre-ICU admission variables
 Age 1.03 (1.01–1.06) < 0.01
 Modified Charlson Comorbidity Score 1.08 (0.94–1.22) 0.26
ICU clinical variablesa
 Ketamine exposure 5.56 (1.09–28.65) 0.04
 Sequential Organ Failure Assessment score 1.09 (0.99–1.20) 0.06
 Presence of coma 2.10 (1.15–3.78) 0.01
 Opioid exposure (IV or oral)b 171.19 (66.45–553.68) < 0.01
 Benzodiazepine exposure (IV or oral)c 34.07 (8.12–235.34) < 0.01
OR = odds ratio.
aPrior to delirium (or ICU discharge).
bAverage IV morphine equivalent dose ≥ 10 mg/d.
cAverage midazolam equivalent dose ≥ 5 mg/d.
Boldface entry indicates the primary result of this study.
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Figure 2. Daily ICU delirium prevalence for those patients administered ketamine who developed incident delirium (n = 54) based on 
the patients remaining in the ICU each day.
TABLE 3. 
Comparison of Ketamine and Nonketamine Patients Who Developed Incident Delirium
Variable







 Age, median (IQR) 64 (56–71) 64 (53–72) 0.95
 Modified Charlson Comorbidity Score, median (IQR) 2 (2–3) 3 (2–4) 0.12
 Admission type, n (%)
  Urgent surgical 29 (54) 95 (34) 0.01
  Medical 25 (46) 183 (66) 0.01
During ICU admission until delirium occurrence
 Sequential Organ Failure Assessment score, median (IQR) 8 (6–10) 8 (6–11) 0.38
 Days with coma, median (IQR) 1 (0–5) 1 (0–3) 0.76
 Opioid use (IV or oral), n (%)a 49 (91) 209 (75) 0.02
  Average daily dose (mg), median (IQR)a 21 (13–45) 18 (10–90) 0.29
 Nonopioid analgesic use, n (%)
  Paracetamol (IV or oral) 46 (85) 229 (82) 0.76
  Pregabalin 2 (4) 10 (4) 1.00
  Gabapentin 1 (2) 3 (1) 0.51
 Sedative use, n (%)
  Propofol 46 (85) 214 (77) 0.25
  Benzodiazepine (IV or oral)b 32 (59) 137 (49) 0.23
  Clonidine (IV) 18 (33) 55 (20) 0.04
  Dexmedetomidine 4 (7) 33 (12) 0.47
 Antipsychotic use, n (%)
  Haloperidol (IV) 0 (0) 0 (0) -
  Quetiapine 0 (0) 0 (0) -
(Continued )
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The ketamine patients in our analysis who developed 
delirium received a median ketamine infusion dose of 
0.5 mg/kg/hr—a dose similar to that reported in other 
ketamine analgosedation studies (9, 11, 12). The un-
desirable psychiatric symptoms of ketamine including 
psychosis and hallucinations are most common at 
doses greater than or equal to 1 mg/kg/hr (7).
The lower frequency of delirium reported in the 
ketamine group of Perbert et al's (11) trial compared 
to our results may be due to the fact ketamine was 
administered as a fixed-dose infusion 2.5 times lower 
in their trial than the average dose administered to 
the patients in our study who developed delirium. 
The results of our prospective cohort analysis are chal-
lenging compared with retrospective, cohort studies 
where the rigor of delirium assessment was unclear 
and important ICU risk factors for delirium including 
daily severity of illness, coma occurrence, and opioid 
and benzodiazepine exposure were not considered 
(1, 2, 8–10).
The reason(s) for the very high prevalence of incident 
delirium we report in the ketamine-exposed patents in 
During ICU admission after delirium occurrence
 Days with delirium, median (IQR) 2 (1–3) 2 (1–5) 0.21
 Delirium subtype, n (%)
  Hypoactive 30 (56) 138 (50) 0.52
  Hyperactive 8 (15) 36 (13) 0.88
  Mixed 16 (30) 104 (37) 0.35
 Opioid use, n (%)a 32 (59) 159 (57) 0.90
 Nonopioid analgesic use, n (%)
  Paracetamol (IV or oral) 45 (83) 241 (87) 0.66
  Pregabalin 4 (7) 10 (4) 0.26
  Gabapentin 0 (0) 3 (1) 1.00
 Sedative use, n (%)
  Propofol 30 (56) 150 (54) 0.95
  Clonidine (IV) 23 (43) 109 (39) 0.75
  Benzodiazepine (IV or oral)b 17 (31) 64 (23) 0.25
  Dexmedetomidine 11 (20) 84 (30) 0.19
 Antipsychotic use, n (%)
  Haloperidol (IV) 38 (70) 169 (61) 0.24
  Quetiapine 5 (9) 36 (13) 0.60
 Days with physical restraint, median (IQR) 4 (0–11) 6 (1–14) 0.39
During entire ICU admission
 Days with mechanical ventilation, median (IQR) 5 (2–11) 7 (3–14) 0.41
 Days in the ICU, median (IQR) 7 (3–13) 9 (4–17) 0.38
 Mortality, n (%) 7 (13) 36 (11) 0.19
IQR = interquartile range.
aAverage IV morphine equivalent dose ≥ 10 mg/d.
bAverage midazolam equivalent dose ≥ 5 mg/d.
TABLE 3. (Continued ).
Comparison of Ketamine and Nonketamine Patients Who Developed Incident Delirium
Variable
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our cohort remains unclear. We carefully considered 
common ICU delirium risk factors and compared de-
lirium characteristics, treatments, and outcomes between 
the ketamine and no-ketamine patients who developed 
ICU incident delirium. Although more ketamine-treated 
patients received opioid therapy prior to delirium, ICU 
opioid exposure prior to delirium occurrence was in-
cluded as a variable in our regression model. Although 
we were not able to evaluate all delirium symptoms, 
some of which may be directly related to the known clin-
ical response to ketamine therapy (e.g., hallucinations), 
the motoric subtypes of delirium we report and use of 
treatments for delirium including restraints, antipsy-
chotics, and dexmedetomidine were similar. Although 
data on the occurrence of severe agitation were not able 
to be collected, the use of sedatives (including IV cloni-
dine and IV haloperidol) and restraints was similar be-
tween the ketamine and nonketamine delirium groups.
Our study has important strengths. We evaluated 
close to 1,000 adults who were critically ill (median 
APACHE-IV score = 67), prospectively collected data 
on both ketamine use and common delirium risk vari-
ables, rigorously evaluated both delirium and coma tid, 
and ensured patients with delirium prior to ketamine in-
itiation were excluded. We then evaluated the risk of ke-
tamine for incident delirium in a regression model that 
accounted for delirium risk variables that were different 
between the delirium and nondelirium groups (4).
Our study also has limitations. The number of patients 
in our cohort who received ketamine was low; ketamine 
analgosedation is most often used in patients with high 
sedative needs. The wide CIs that surround the odds 
ratios for delirium risk we present weaken the preci-
sion of our findings. A consistent approach for ketamine 
analgosedation prescribing was not in place throughout 
the study; the specific prescribing rationale for ketamine 
initiation and titration was not known. The high pro-
portion of ketamine patients who developed incident 
delirium precluded determining whether the ketamine 
dose or infusion duration affects this risk. Delirium risk 
factors not included in our analysis may have affected our 
results. For patients having delirium prior to or on the 
same day of ketamine initiation, the contributory effect 
of ketamine to delirium occurrence remains unknown.
We were not able to consider whether the time from 
ICU admission to ketamine initiation affects delirium 
risk. The results of our single-hospital analysis may be 
different in ICUs where ketamine prescribing practices 
are different, patients have different delirium risks, or 
delirium prevention and treatment strategies are dif-
ferent or unavailable (e.g., IV clonidine). Some of the 
delirium treatment strategies may have been used for 
nondelirium treatment indications (e.g., haloperidol 
for postoperative nausea and vomiting). We did not 
collect data on daily ABCDEF bundle use. Although all 
ICU variables were collected and considered only be-
fore ICU delirium occurrence (if it occurred), formal 
time-dependent analytic approaches were not used, and 
thus, residual confounding may have occurred (5, 6). 
Finally, the presence of psychiatric symptoms known 
to be associated with ketamine use but not detected by 
the CAM-ICU (e.g., hallucinations and psychosis) was 
not collected (4, 7, 20).
CONCLUSION
In conclusion, our study suggests ketamine anal-
gosedation in critically ill surgical and medical adults 
may contribute to an increased risk for incident ICU 
delirium. Despite the extensive comparative analyses 
conducted between the ketamine and nonketamine 
groups who developed delirium, the mechanisms for 
delirium in patients receiving ketamine analgeseda-
tion remain unclear. Future, well-designed, prospec-
tive, randomized trials are needed to carefully evaluate 
the magnitude of delirium risk associated ketamine 
analgosedation and whether psychiatric symptoms 
observed during ketamine therapy truly represent 
delirium.
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